Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide.
Phoebe A TsaoJennifer BurnsKyle KumbierJordan B SparksShami EntenmanLindsey E BloorAmy S B BohnertTed A SkolarusMegan E V CaramPublished in: Cancer medicine (2023)
We found no overall differences in mental health care utilization between CRPC patients who received first-line abiraterone versus enzalutamide. However, men with preexisting mental health diagnoses received the majority of mental health care and had more mental health visits with enzalutamide.